Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Sci Signal. 2019 Oct 1;12(601):eaay0482. doi: 10.1126/scisignal.aay0482

Fig. 5. Palbociclib and PT2399 synergistically suppress cell viability of VHL-null cells in PT2399-sensitive, but not PT2399-insensitive, ccRCC cell lines.

Fig. 5.

(A) Ratio of VHL-Tdtomato–expressing to EV-GFP–expressing 786-O cells that were mixed (1:1) and then treated with 0, 200, or 400 nM palbociclib with or without 2 μM PT2399 for 10 days. Data are means ± SD of n = 3 independent experiments. (B to D) As described for (A) in A498 (B), UMRC-2 (C), and 769-P (D) cells. (E) Relative mRNA expression for CCND1 in EV-GFP–expressing 786-O cells treated with 2 μM PT2399, 400 nM palbociclib, or the combination (as indicated) for 48 hours. Data are means ± SD of n = 2 independent experiments. (F to H) As described for (E) in A498 (F), UMRC-2 (G), and 769-P (H) cells. **P < 0.01, ***P < 0.001, and ****P < 0.0001 by two-way ANOVA.